Learn about Lucas Galimany’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, he shares how the program helped his personally and professionally.
Please join us in warmly welcoming Daniela Armijo, Ncoza Dlova, Benjamín Hidalgo Matlock, and Wilson Liao as IPC’s newest Councilors for 2023.
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
This blog post provides a comprehensive overview of psoriasis in individuals with skin of color. It explores the prevalence of psoriasis in different ethnic groups worldwide and highlights potential underestimations due to healthcare barriers. The article discusses genetic variations in psoriasis susceptibility among ethnic groups and the challenges in diagnosing psoriasis in darker-skinned individuals. It emphasizes the need for inclusive dermatology education and resources that incorporate skin of color to improve clinical competency. The impact of psoriasis on quality of life, specifically in non-white individuals, and the importance of developing better measurement tools for diverse ethnicities are examined. The blog post also addresses treatment approaches for psoriasis in diverse ethnic populations and the ongoing efforts to include patients of different ethnicities in clinical trials.
The International Society of Investigative Dermatology (ISID) held its inaugural meeting in Tokyo, Japan, from May 10 – 13, 2023. IPC’s Symposium: Disease Memory and Disease Modification in Psoriasis, addressed tissue-resident memory cells, epigenetic inflammatory memory, disease modification, and future directions in psoriasis research. The following congress report includes 12 summaries of the most crucial psoriasis sessions.
Learn about Mona El-Kalioby’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her personally and professionally.
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on the topline results from the EFFISAYIL™ 2 trial.
Learn about Juul van den Reek’s experience as a 2022 participant in IPC’s International Fellowship Program. In this exclusive interview, she shares how the program helped her expand her psoriasis research internationally and build valuable connections with experts in the field.
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Introducing IPC’s newest Councilors for 2023: A cohort of global experts dedicated to improving patient care for psoriasis.
The International Psoriasis Council (IPC) has made significant progress in advancing psoriasis care and research worldwide in the first quarter of 2023. We invite you to watch our 2-minute video that highlights our key achievements.
